Proscia, a provider of AI-enabled digital pathology solutions, is collaborating with Royal Philips to advance an open ecosystem that helps laboratories accelerate and scale digital pathology adoption. Through the collaboration, Proscia will integrate the Philips Pathology SDK to natively utilize Philips’ iSyntax image format with its Concentriq digital pathology platform and suite of AI modules, providing users of Philips' digital pathology solutions with expanded options to meet their business and workflow needs.  By incorporating the Philips medical-grade iSyntax image format into Concentriq, Philips and Proscia are providing laboratories with the freedom to choose the best components of an integrated digital pathology ecosystem and realize added value from their images.  “We’re pleased to collaborate with Philips to deliver on our shared vision of an open digital pathology ecosystem,” said Coleman Stavish, Proscia’s Chief Technology Officer. “Our integrated solution is empowering a best-in-class approach to scanning, image management, and computational pathology that builds upon the industry-leading iSyntax format and provides laboratories with a future-proof approach for scaling their digital implementations.”

Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product 'qER'. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product. Now, the AI tool can be used to triage radiology scans with intracranial bleeds, mass effect, midline shift, and cranial fractures. Two of these capabilities – cranial fractures and midline shift – are exclusive to Qure.ai's product. This means that the newly cleared qER suite will be able to triage nearly all critical abnormalities visible on routine head CT scans.  The qER suite plugs directly into the radiology workflow and prioritizes critical cases on the worklist. This triage drastically reduces the time taken to open critical scans, so those with time-sensitive abnormalities get to be read and reported faster, leading to better patient outcomes. The qER product has undergone extensive validation including a 2018 peer-reviewed publication in The Lancet and has been actively deployed at many hospitals and teleradiology providers globally.  Qure.ai's other products include a CE-marked chest X-ray AI tool qXR, and COVID-19 progression monitoring solutions for chest X-rays, with both in clinical use in over 20 countries.

Recent Headlines

Qure.ai Bags Industry's First 4-In-1 FDA Clearance For Medical Imaging AI | June 30 2020
Philips And Proscia Collaborate To Advance Open Digital Pathology Ecosystem | June 30 2020
Dutch Artificial Intelligence Firm Collects $2.3M To Fuel Prostate Cancer Solution | June 30 2020
UK’s First Rollout Of AI-Based Cancer Detection For NHS Patients As Pathology Provider LDPath Teams | June 30 2020
ContextVision Announces First CE Marked Digital Pathology Product | June 29 2020
Roche Digital Pathology Algorithm For NSCLC Receives CE Mark | June 26 2020
Mayo Clinic Launches Imaging Solution To Enable Digital Pathology Across The Enterprise | June 25 2020
Taiwanese Artificial Intelligence Startup Offering Faster Brain CT Reads Raises $2.7M | June 24 2020

Australian Government Sinks AU$19 Million Into AI Health Research Projects | June 29 2020
Advanced MRI Used For Heart Disease Could Detect Neuroblastoma In Kids | June 29 2020
PathAI And Bristol Myers Squibb Find Positive Association Of Digital PD-L1 Expression With Outcomes In Nivolumab-Treated Patients In An Exploratory Analysis | June 26 2020
Machine Learning Provides Radiologists A Cost-Effective Assist To Deduce Lung Cancer Severity From CT | June 26 2020
AI Dual-Stain Approach Improved Accuracy, Efficiency Of Cervical Cancer Screening In NIH Study | June 25 2020
AI Classifies Colorectal Cancer Pathology Samples Within 30 Minutes | June 24 2020